No Action Required for 4+ Glucosuria on Jardiance
Glucosuria (4+ glucose on urine dipstick) is the expected and intended therapeutic mechanism of Jardiance (empagliflozin) and requires no intervention. This is not a complication—it is how the drug works.
Why This Is Normal and Expected
Jardiance is an SGLT2 inhibitor that works by blocking glucose reabsorption in the proximal renal tubule, deliberately causing glucose to spill into the urine 1. The FDA label explicitly states that empagliflozin increases urinary glucose excretion to approximately 64-78 grams per day with therapeutic doses 1. This glucosuria:
- Begins immediately after the first dose
- Persists throughout treatment (this is the mechanism of action)
- Is independent of blood glucose levels
- Provides cardiovascular and renal benefits beyond glucose lowering 2
The FDA label specifically notes: "When taking JARDIANCE, you may have sugar in your urine, which will show up on a urine test" 1. This is documented, anticipated, and not a reason for concern or dose adjustment.
What You Should Actually Monitor
Instead of being concerned about the glucosuria itself, focus on these clinically relevant issues:
1. Genital Mycotic Infections (Most Common Side Effect)
- More frequent in women
- Mitigate with genital hygiene
- Treat with over-the-counter antifungals if symptomatic 2
2. Volume Status and Blood Pressure
- Monitor for signs of intravascular volume depletion
- Check blood pressure, especially if patient is on other diuretics
- Assess kidney function at baseline and periodically 2
3. Diabetic Ketoacidosis Risk (Rare but Serious)
- Discontinue 3-4 days before scheduled surgery
- Stop during critical illness or prolonged fasting
- Be aware of euglycemic DKA (can occur with normal blood glucose) 2
4. Urinary Tract Infections
- Monitor for dysuria, urgency, frequency, fever, or flank pain
- Serious UTIs requiring hospitalization have been reported 1
Common Pitfall to Avoid
Do not stop or reduce Jardiance because of glucosuria. The 2025 ADA guidelines emphasize that SGLT2 inhibitors like empagliflozin provide cardiovascular and kidney benefits that are independent of their glucose-lowering effects 2. Even when eGFR falls below 45 mL/min/1.73 m² (where glucose-lowering efficacy is minimal), guidelines recommend continuing the medication for cardiovascular and kidney protection until dialysis or transplantation 2.
The Bottom Line
The presence of 4+ glucose in urine while on Jardiance is pharmacologically expected and therapeutically desirable. It reflects the drug working as intended through SGLT2 inhibition 1. Continue the medication and monitor for actual adverse effects (infections, volume depletion, DKA risk factors) rather than the intended glucosuria itself.